Santarus, Pharming Announce New Data From RUCONEST's Repeat Treatment Study

(RTTNews) - Santarus, Inc. (SNTS) and Pharming Group NV, Friday said that new data from an open-label extension of the pivotal Phase III clinical study with RUCONEST, will be featured in a poster presentation on November 9 and 10, at the 2013 American College of Allergy, Asthma & Immunology Annual Scientific Meeting. RUCONEST was administered for the treatment of 224 repeat acute angioedema attacks in 44 patients with hereditary angioedema or HAE following initial treatment in the clinical study. RUCONEST improved symptoms of acute hereditary angioedema attacks with similar results for repeated treatments, the company said.

RUCONEST, is a recombinant version of the human protein C1 esterase inhibitor, and is produced with Pharming's proprietary transgenic technology. The inhibitor is approved in Europe for the treatment of acute angioedema attacks in patients with HAE. RUCONEST is an investigational drug in the U.S. and received the orphan drug designation from FDA for the treatment of acute attacks of HAE.